Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana L Ruano

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|September 10, 2011
The process of social participation in primary health care: the case of Palencia, GuatemalaAna L Ruano, Miguel S Sebastián, Anna-Karin Hurtig
Archives of Pathology & Laboratory Medicine|February 26, 2024
Male Invasive Lobular Breast Cancer: Clinicopathologic Features Including Recurrence Score Results From a Population-Based DatabaseMichael Balatico, Ana L Ruano, Allison S Cleary, et al.
American Journal of Clinical Oncology|September 14, 2023
Metaplastic Breast Carcinoma: Clinicopathologic Features and Recurrence Score Results From a Population-based DatabaseValarie McMurtry, Allison S Cleary, Ana L Ruano, et al.
Archives of Pathology & Laboratory Medicine|November 7, 2023
Clinicopathologic Features of 2018 American Society of Clinical Oncology/College of American Pathologists Fluorescence In Situ Hybridization Group 3 Breast Carcinoma (Human Epidermal Growth Factor Receptor 2 Chromosome 17 Centromere Ratio <2.0 and Average Human Epidermal Growth Factor Receptor 2 Copy Number ≥6.0)Diane Wilcock, Deepika Sirohi, Daniel Albertson, et al.
American Journal of Clinical Pathology|February 12, 2025
HER2 fluorescence in situ hybridization groups 2-4 breast cancers classified as positive after targeted recounts following equivocal (2+) immunohistochemistryDiane Wilcock, Deepika Sirohi, Joshua F Coleman, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|January 27, 2025
Changes in HER2 Amplification Status for Breast Cancer Patients After Immunohistochemistry Directed In Situ HybridizationCameron Beech, Diane M Wilcock, Kristina H Moore, et al.
Archives of Pathology & Laboratory Medicine|March 15, 2023
Quantitative Imaging Analysis Fluorescence In Situ Hybridization Validation for Clinical HER2 Testing in Breast CancerDiane M Wilcock, Kristina H Moore, Leslie Rowe, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|September 10, 2011
The process of social participation in primary health care: the case of Palencia, GuatemalaAna L Ruano, Miguel S Sebastián, Anna-Karin Hurtig
Archives of Pathology & Laboratory Medicine|February 26, 2024
Male Invasive Lobular Breast Cancer: Clinicopathologic Features Including Recurrence Score Results From a Population-Based DatabaseMichael Balatico, Ana L Ruano, Allison S Cleary, et al.
American Journal of Clinical Oncology|September 14, 2023
Metaplastic Breast Carcinoma: Clinicopathologic Features and Recurrence Score Results From a Population-based DatabaseValarie McMurtry, Allison S Cleary, Ana L Ruano, et al.
Archives of Pathology & Laboratory Medicine|November 7, 2023
Clinicopathologic Features of 2018 American Society of Clinical Oncology/College of American Pathologists Fluorescence In Situ Hybridization Group 3 Breast Carcinoma (Human Epidermal Growth Factor Receptor 2 Chromosome 17 Centromere Ratio <2.0 and Average Human Epidermal Growth Factor Receptor 2 Copy Number ≥6.0)Diane Wilcock, Deepika Sirohi, Daniel Albertson, et al.
American Journal of Clinical Pathology|February 12, 2025
HER2 fluorescence in situ hybridization groups 2-4 breast cancers classified as positive after targeted recounts following equivocal (2+) immunohistochemistryDiane Wilcock, Deepika Sirohi, Joshua F Coleman, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|January 27, 2025
Changes in HER2 Amplification Status for Breast Cancer Patients After Immunohistochemistry Directed In Situ HybridizationCameron Beech, Diane M Wilcock, Kristina H Moore, et al.
Archives of Pathology & Laboratory Medicine|March 15, 2023
Quantitative Imaging Analysis Fluorescence In Situ Hybridization Validation for Clinical HER2 Testing in Breast CancerDiane M Wilcock, Kristina H Moore, Leslie Rowe, et al.
Pageof 1